Trial Profile
Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cancer metastases; Liver metastases; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 06 Jun 2023 Results assessing partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 02 Mar 2023 Planned End Date changed from 1 Jul 2022 to 1 Nov 2026.
- 14 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Jul 2022.